EQUATOR Oncology Project
The EQUATOR mission is to achieve accurate, complete, and transparent reporting of all health research studies to support research reproducibility and usefulness. In addition to our main EQUATOR website we have begun compiling specialist collections of resources about reporting for individual specialties which we hope will provide practical help to clinicians and researchers in the implementation of reporting guidelines within their research. This oncology specialist collection is the first such collection and it is at an early stage of development. In the meantime, whilst we develop a comprehensive resource, we hope that the information and resources highlighted here are helpful to oncology researchers.
About this specialty resource
EQUATOR Oncology Project Current Awareness Bulletin
Useful resources and references for oncology researchers
National Cancer Research Institute (NCRI) 2016 conference
The EQUATOR Oncology Project lead (Angela MacCarthy) recently attended the National Cancer Research Institute (NCRI) 2016 conference in Liverpool, UK. Angela presented a poster, describing (i) some recent research on the quality of oncology trial reporting for publication and (ii) the EQUATOR Oncology Project. View the poster (PDF)
- Filleron T, Kouokam W, Gilhodes J, Duhamel A, Penel N, Joly F, Tresch-Bruneel E, Kramar A, Houédé N. Statistical controversies in clinical research: should schedules of tumor size assessments be changed? Ann Oncol. 2016;27(11):1981-1987. PMID: 27502711
- Michiels S, Ternès N, Rotolo F. Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Ann Oncol. 2016 Sep 15. pii: mdw307. PMID: 27634691
- Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2016 Oct 11. pii: mdw413. PMID: 27733372
- Gleiss A, Zeillinger R, Braicu EI, Trillsch F, Vergote I, Schemper M. Statistical controversies in clinical research: the importance of importance. Ann Oncol. 2016;27(7):1185-9. PMID: 27052655
- Del Paggio JC, Azariah B, Sullivan R, Hopman WM, James FV, Roshni S, Tannock IF, Booth CM. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? Ann Oncol. 2016 Oct 13. pii: mdw538. PMID: 27742650
- Mansouri A, Shin S, Cooper B, Srivastava A, Bhandari M, Kondziolka D. Randomized controlled trials and neuro-oncology: should alternative designs be considered? J Neurooncol. 2015;124(3):345-56. PMID: 26297044
- Schandelmaier S, Conen K, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto, Amstutz A, Bengough T, Meerpohl JJ, Stegert M, Olu KK, Tikkinen KA, Neumann I13, Carrasco-Labra A, Faulhaber M, Mulla SM, Mertz D, Akl EA, Sun X, Bassler D, Busse JW, Ferreira-González I, Lamontagne F, Nordmann A, Gloy V, Raatz H, Moja L, Rosenthal R, Ebrahim S, Vandvik PO, Johnston BC, Walter MA, Burnand B, Schwenkglenks M, Hemkens LG, Bucher HC, Guyatt GH, Briel M, Kasenda B; DISCO study group. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2015;26(9):1966-73. PMID: 26133966
- Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™). Ann Oncol. 2016 Sep 28. pii: mdw422. PMID: 27681863
- Shi Q, Mendoza TR, Wang XS, Cleeland CS. Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. Eur J Cancer. 2016;67:83-90. PMID: 27620946
- de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky F, Nicholas LH, O’Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity. Cancer. 2016 Oct 7. PMID: 27716900
Visit our archive of previously highlighted new publications and resources of interest.
The development of this cancer-specific project within the EQUATOR Network is funded by Cancer Research UK (CRUK).
We welcome your comments and suggestions on the development of this project. Please email us at: email@example.com
This page was last updated on: 25 November 2016